Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; mannitol; calcium hydrogen phosphate dihydrate; purified water; hyprolose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - ticagrelor, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

astrazeneca limited - ticagrelor 90mg;  ;  ;   - film coated tablet - 90 mg - active: ticagrelor 90mg       excipient: calcium hydrogen phosphate hyprolose hypromellose iron oxide yellow macrogol 400 magnesium stearate mannitol purified talc purified water   sodium starch glycolate titanium dioxide - brilinta, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) · in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). · in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; iron oxide yellow; macrogol 400; hypromellose; mannitol; calcium hydrogen phosphate dihydrate; titanium dioxide; magnesium stearate; sodium starch glycollate type a - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Canada - Tiếng Anh - Health Canada

teva canada limited - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate magnesium stearate mannitol opadry yellow 00f520007 povidone purified water sodium starch glycolate - ticagrelor-teva, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke), - in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg) and - in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

viatris limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate dihydrate croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 32k520044 - ticagrelor mylan, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Singapore - Tiếng Anh - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - ticagrelor - tablet, film coated - 90 mg - ticagrelor 90 mg

Canada - Tiếng Anh - Health Canada

jamp pharma corporation - ticagrelor - tablet - 90mg - ticagrelor 90mg

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, dispersible - excipient ingredients: mannitol; microcrystalline cellulose; crospovidone; xylitol; calcium hydrogen phosphate; sodium stearylfumarate; hyprolose; colloidal anhydrous silica - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - ticagrelor - film-coated tablet - 60 milligram(s) - ticagrelor